Clovis investors feel more Lynparza pressure
As Lynparza threatens Rubraca in prostate cancer, investors should now focus on whether Astra will show a benefit in the ATM-mutant patient population.
Opdivo’s lung cancer latest: one fail, one shrug
Bristol-Myers Squibb’s byzantine Checkmate-227 study yields one flop and one technical success that, in reality, counts for nothing.
Asco 2019 – Polo reveals an overall survival hole
The keenly awaited study of Lynparza in pancreatic cancer maintenance fails to show much beyond its headline primary endpoint of progression-free survival.
Asco 2019 – top marks for effort to Merck & Co in gastric cancer
A first-line Keytruda study is nominally positive, but numerous questions remain before approval can be assured.
Keytruda looks to secure a June double play
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Colorectal cancer could see Array stand alone at last
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
GW sets its sights on Zogenix and a new Epidiolex use
A strong pivotal result should allow the company to broaden Epidiolex’s reach to tuberous sclerosis complex, as long as liver injury risk can be ruled out.
EASL 2019 – Intercept and medics clash in Nash
Yesterday’s high-profile presentation of the Regenerate trial failed to quash concerns about Ocaliva in Nash, despite Intercept’s best attempts to polish the data.
Events overtake Bavencio in ovarian cancer
Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.